Drug Profile
Inbakicept - ImmunityBio
Alternative Names: ALT 803; Anktiva; Fusion protein consisting of IL-15N72D and IL-15RaSu/FC; IL-15N72D/IL-15Ra-Fc; IL-15N72D:IL-15RaSu/Fc fusion complex; IL-15N72D:IL-15RαSu/Fc fusion protein complex; interleukin-15 (IL-15) superagonist complex; N-803; Nogapendekin alfa; Nogapendekin alfa inbakicept; Superagonist Interleukin-15:Interleukin-15 Receptor AlphaSu/Fc Fusion Complex Alt-803; VesAnktiva™Latest Information Update: 27 Mar 2024
Price :
$50
*
At a glance
- Originator Altor BioScience Corporation; NantKwest
- Developer AIDS Clinical Trials Group; Altor BioScience Corporation; ImmunityBio; Masonic Cancer Center; National Cancer Institute (USA); National Institute of Allergy and Infectious Diseases; Thai Red Cross AIDS Research Centre; University of Minnesota; University of South Carolina; Walter Reed Army Institute of Research
- Class Antibacterials; Antineoplastics; Antivirals; Immunoglobulin Fc fragments; Immunotherapies; Interleukins; Recombinant fusion proteins
- Mechanism of Action Interleukin-15 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Bladder cancer
- Phase III Non-small cell lung cancer
- Phase II Acute myeloid leukaemia; Cervical cancer; Colorectal cancer; Gastric cancer; Hereditary nonpolyposis colorectal cancer; HIV infections; Liver cancer; Malignant melanoma; Merkel cell carcinoma; Oesophageal cancer; Pancreatic cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
- Phase I/II Haematological malignancies; Multiple myeloma; Non-Hodgkin's lymphoma; Triple negative breast cancer
- Phase I HIV-1 infections
- No development reported Bacterial infections; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Most Recent Events
- 20 Mar 2024 Dana-Farber Cancer Institute and ImmunityBio plans a phase I trial for Ovarian cancer (Recurrent, Combination therapy, Second-line therapy or greater, In adults, In elderly) in USA (NCT06321484)
- 12 Mar 2024 Dana-Farber Cancer Institute in collaboration with ImmunityBio plans a phase 0 trial in Urogenital cancer/Renal Cell Carcinoma (Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy) in USA (IV, infusion) in April 2024 (NCT06318871)
- 06 Mar 2024 Pharmacodynamics data from a preclinical studies in HIV infections released by ImmunityBio